Avalon GloboCare Corp., a clinical-stage global developer of cell-based technologies and therapeutics, announced a strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria to develop an S-layer vaccine that can be administered by an intranasal or oral route against SARS-CoV-2, the novel coronavirus that causes COVID-19 disease.
The principal investigator of the co-development project is BOKU’s Professor Uwe B. Sleytr, an eminent member of the Austrian Academy of Sciences. Professor Sleytr is a pioneer of applied surface layer (“S-layer”) nanotechnology, based on the repetitive protein structures that make up the outer surface of microbial cells. Dr. Eva-Kathrin Ehmoser, Professor and Head of the Institute for Synthetic Bioarchitectures at BOKU, serves as the co-principal investigator of the COVID-19 vaccine program.
Given the continued rise of COVID-19 cases around the world, Avalon and the BOKU scientists are working closely to co-develop a novel SARS-CoV-2 vaccine that would induce a sufficient immune response to prevent a severe form of COVID-19, which causes morbidity and often mortality. This vaccine strategy has the dual advantages of ease of manufacturing and delivery. The candidate vaccine is derived from a fusion of an S-layer viral particle mimic with the SARS-CoV-2 spike protein and could be delivered non-invasively via the nasal or oral passageways, rather than a needle-based injection into the muscle or under the skin. The S-layer protein-based vaccine is expected to both decrease the severity of a SARS-CoV-2 infection—preventing the more severe respiratory inflammation and organ damage seen in many COVID-19 patients—and build immunity against the virus.
This strategic partnership with BOKU leverages Avalon’s expertise and resources in bio-manufacturing infrastructure and clinical study implementation with the scientific capabilities and deep experience of the laboratories of Professors Sleytr and Ehmoser at BOKU. Professors Sleytr and Ehmoser have already made substantial progress by developing the proprietary techniques necessary to synthesize conjugate vaccines consisting of an S-layer artificial viral envelope linked to a viral antigen. As a proof of concept, the investigators have also shown that these types of protein conjugate vaccine candidates are able to elicit immune-protective antibody responses.
Avalon and Professor Sleytr have jointly filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) pertaining to the nanoparticle S-layer based vaccine against SARS-CoV-2.
The research is part of an ongoing and broader collaboration between Avalon and BOKU that will utilize S-layer technology to accelerate additional vaccine programs for other respiratory infections including different strains of the flu (influenza A/B), respiratory syncytial virus (RSV), and other viruses. As part of the partnership, Avalon is also actively exploring other practical uses of S-layer technology including targeted drug delivery, diagnostic devices, and therapeutic applications.
“We are encouraged by the progress we have made so far to develop a novel COVID-19 vaccine during this unprecedented world-wide health crisis,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “We are working swiftly and diligently with BOKU to complete the laboratory testing and characterization of the S-layer fusion protein SARS-CoV-2 vaccine candidate. We believe that our novel vaccine approach has the potential to be effective. Importantly, this vaccine candidate could be manufactured and delivered more rapidly compared to traditional vaccines, providing access and immunization to a larger population of people around the globe to help combat the COVID-19 pandemic.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. is a clinical-stage, vertically-integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEXTM), and regenerative therapeutics.
